Zambon, a privately-owned pharmaceutical company based in Italy, has entered into a long-term agreement with flu-vaccine specialists Seqirus to commercialize Xadago (safinamide) in Australia and New Zealand.
Xadago was developed by Italian firm Newron Pharmaceuticals (SIX: NWRN), a biotech company developing novel therapies for patients with diseases of the central nervous system.
Xadago is a new chemical entity for treating Parkinson’s disease, with a unique mode of action. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over two years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze